title: Universal vs Risk Factor Screening for Methicillin-Resistant Staphylococcus aureus in a Large Multicenter Tertiary Care Facility in Canada.
abstract: OBJECTIVE To assess the clinical effectiveness of a universal screening program compared with a risk factor-based program in reducing the rates of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) among admitted patients at the Ottawa Hospital. DESIGN Quasi-experimental study. SETTING Ottawa Hospital, a multicenter tertiary care facility with 3 main campuses, approximately 47,000 admissions per year, and 1,200 beds. METHODS From January 1, 2006 through December 31, 2007 (24 months), admitted patients underwent risk factor-based MRSA screening. From January 1, 2008 through August 31, 2009 (20 months), all patients admitted underwent universal MRSA screening. To measure the effectiveness of this intervention, segmented regression modeling was used to examine monthly nosocomial MRSA incidence rates per 100,000 patient-days before and during the intervention period. To assess secular trends, nosocomial Clostridium difficile infection, mupirocin prescriptions, and regional MRSA rates were investigated as controls. RESULTS The nosocomial MRSA incidence rate was 46.79 cases per 100,000 patient-days, with no significant differences before and after intervention. The MRSA detection rate per 1,000 admissions increased from 9.8 during risk factor-based screening to 26.2 during universal screening. A total of 644 new nosocomial MRSA cases were observed in 1,448,488 patient-days, 323 during risk factor-based screening and 321 during universal screening. Secular trends in C. difficile infection rates and mupirocin prescriptions remained stable after the intervention whereas population-level MRSA rates decreased. CONCLUSION At Ottawa Hospital, the introduction of universal MRSA admission screening did not significantly affect the rates of nosocomial MRSA compared with risk factor-based screening. Infect. Control Hosp. Epidemiol. 2015;37(1):41-48.
authors.affiliation: 1Department of Medicine,the Ottawa Hospital and University of Ottawa,Ottawa,Ontario,Canada.
authors.forename: V R
authors.initials: VR
authors.lastname: Roth
authors.affiliation: 3Department of Epidemiology and Community Medicine,University of Ottawa,Ottawa,Ontario,Canada.
authors.forename: T
authors.initials: T
authors.lastname: Longpre
authors.affiliation: 2Ottawa Hospital Research Institute,Ottawa,Ontario,Canada.
authors.forename: M
authors.initials: M
authors.lastname: Taljaard
authors.affiliation: 2Ottawa Hospital Research Institute,Ottawa,Ontario,Canada.
authors.forename: D
authors.initials: D
authors.lastname: Coyle
authors.affiliation: 1Department of Medicine,the Ottawa Hospital and University of Ottawa,Ottawa,Ontario,Canada.
authors.forename: K N
authors.initials: KN
authors.lastname: Suh
authors.affiliation: 4School of Population and Public Health,University of British Columbia,Vancouver,British Columbia,Canada.
authors.forename: K A
authors.initials: KA
authors.lastname: Muldoon
authors.affiliation: 2Ottawa Hospital Research Institute,Ottawa,Ontario,Canada.
authors.forename: K
authors.initials: K
authors.lastname: Ramotar
authors.affiliation: 1Department of Medicine,the Ottawa Hospital and University of Ottawa,Ottawa,Ontario,Canada.
authors.forename: A
authors.initials: A
authors.lastname: Forster
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002170:Canada / Q000453:epidemiology; D016360:Clostridioides difficile; D003015:Clostridium Infections / Q000453:epidemiology*; D003428:Cross Infection / Q000175:diagnosis* / Q000453:epidemiology* / Q000382:microbiology; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008403:Mass Screening / Q000379:methods*; D055624:Methicillin-Resistant Staphylococcus aureus; D008875:Middle Aged; D016712:Mupirocin / Q000627:therapeutic use; D012307:Risk Factors; D013203:Staphylococcal Infections / Q000175:diagnosis* / Q000453:epidemiology* / Q000382:microbiology; D062606:Tertiary Care Centers
chemical_list: D000900:Anti-Bacterial Agents; D016712:Mupirocin